Core Insights - Safe Pro Group Inc. has been awarded a $1,000,000 subcontract to supply AI processing systems to the U.S. Government through a prime contractor, indicating a significant business opportunity for the company in the defense sector [1] Company Overview - Safe Pro Group Inc. (NASDAQ: SPAI) specializes in AI-enabled security and defense solutions, providing advanced situational awareness tools for various applications including defense, humanitarian, and homeland security [4] - The company utilizes proprietary machine learning and computer vision technology to enhance drone imagery processing, allowing for rapid identification of explosive threats, which offers a safer alternative to traditional human analysis methods [4] - Safe Pro's platform is cloud-based and powered by Amazon Web Services (AWS), targeting multiple markets such as commercial, government, law enforcement, and humanitarian sectors [4] Strategic Partnerships - The internal development and low rate initial production (LRIP) for the awarded systems were funded through strategic investments from notable U.S. firms, including ONDAS Inc. and Unusual Machines Inc. [1]

Company Overview - ALK-Abelló A/S is a global specialty pharmaceutical company focused on allergy treatment, covering the entire value chain from development to marketing of products for diagnosing and treating respiratory allergies and severe allergic reactions [3]. Annual General Meeting - The Annual General Meeting of ALK-Abelló A/S is scheduled for Monday, 16 March 2026, at 4:00 PM (CET) in Hørsholm, Denmark [1]. - The agenda for the meeting includes complete proposals from the Board of Directors [1]. Employment and Market Presence - ALK employs approximately 2,700 people worldwide and is listed on Nasdaq Copenhagen under the ticker ALK B [3].

Core Insights - Senti Biosciences, Inc. is advancing its proprietary Gene Circuit platform for next-generation cell and gene therapies, participating in a Cell & Gene Live virtual event to discuss innovative cell therapy technologies [1][2][3] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing cell and gene therapies for incurable diseases, utilizing synthetic biology to engineer Gene Circuits that enhance precision and control in targeting cancer cells while sparing healthy cells [6] Product Development - SENTI-202 is the first Logic Gated off-the-shelf CAR-NK cell therapy designed to target CD33 and/or FLT3 expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while protecting healthy bone marrow cells [4] - The therapy includes an OR GATE for targeting cancer cells, a NOT GATE to protect healthy cells, and calibrated-release IL-15 to enhance cell persistence and activity [4] - Currently, Senti Bio is enrolling adult patients with relapsed/refractory CD33 and/or FLT3 expressing hematologic malignancies in a Phase 1 clinical trial for SENTI-202, which may become a first-in-class allogeneic treatment for AML/MDS patients [4] Regulatory Designations - The FDA has granted Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 for treating relapsed/refractory hematologic malignancies, including AML [5]

Core Insights - ParaZero Technologies Ltd. has received an additional order for its DefendAir™ multi-layered Counter-UAS solution from a second branch of an Israeli defense entity, indicating growing trust in its technology [1][2][3] Group 1: Product Effectiveness - The new order highlights DefendAir's effectiveness, achieving 100% interception rates against high-speed threats, including FPV kamikaze drones and heavy-lift logistics platforms [2] - DefendAir features a non-explosive, patent-protected net-launching mechanism, providing a safe and cost-effective alternative to traditional counter-UAS methods [2] Group 2: Company Vision and Partnerships - The CEO of ParaZero expressed enthusiasm about deepening partnerships with Israeli defense entities, viewing the contract as validation of their innovative solutions that enhance national security [3] - The company aims to support more defense entities globally with its advanced systems and expert training [3] Group 3: Company Overview - ParaZero Technologies, founded in 2014, specializes in smart, autonomous solutions for the UAS industry, with a product portfolio that includes SafeAir, DefendAir, and DropAir [4] - The company's mission is to redefine aerial operations with intelligent systems that enhance safety, scalability, and security [4] Group 4: Additional Offerings - ParaZero offers specialized launchers for rapid deployment in various environments, enabling soft-kill interception of hostile drones with minimal collateral damage [6] - The company provides interception pods compatible with various configurations, ensuring layered defense for troops and critical infrastructure [6] - A comprehensive training package is available, including simulation-based and live-fire training modules to ensure operational readiness [6]

Core Insights - 20/20 BioLabs, Inc. is an early market leader in AI-powered laboratory-based blood tests for early detection and prevention of cancers and chronic diseases [3][5] - The company will host a virtual investor webinar on February 26, 2026, to discuss its recent Nasdaq listing and product offerings [4][5] - The company offers two main products: OneTest™ for Cancer™, a multi-cancer early detection blood test, and OneTest for Longevity™, which measures inflammatory biomarkers [5][6] Company Overview - 20/20 BioLabs was listed on Nasdaq under the ticker symbol "AIDX" on February 19, 2026 [5] - The company operates a CAP-accredited and CLIA-licensed laboratory in Gaithersburg, MD, where tests are conducted [6] - The company also runs a Clinical Laboratory Innovation Accelerator (CLIAx) to support overseas diagnostics start-ups [7] Upcoming Initiatives - The OneTest for Longevity™ is expected to launch before the end of February 2026 [4] - The virtual investor webinar will include a question-and-answer session, allowing investors to engage directly with the company's leadership [4][5]

Core Insights - Oncotelic Therapeutics Inc. has been featured in an editorial by BioMedWire, highlighting its strategic positioning within the biotechnology sector [1][2] Industry Trends - Biotechnology mergers and acquisitions are increasingly focused on clinical-stage and late-stage programs that are backed by human data, moving away from early discovery platforms with uncertain timelines [2] - Investors are now prioritizing assets that show safety signals, efficacy data, and clearer pathways to commercialization, indicating a shift in investment strategies within the sector [2] Company Overview - Oncotelic Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing oncology and immunotherapy products, particularly targeting high-unmet-need cancers and rare pediatric indications [4] - The company has expanded its international intellectual property coverage for its proprietary TGF-β antisense therapeutic platform, OT-101, enhancing its protection across neurology, oncology, and CNS drug-delivery technologies [3] - Oncotelic holds a 45% stake in GMP Bio, a joint venture that is advancing its own pipeline of drug candidates, further strengthening Oncotelic's strategic position in oncology and rare disease therapeutics [4]

Regulatory clearance enables start of clinical testing and marks transition to clinical-stage companyOn track for initial clinical data to emerge from mid-2026 Oslo, Norway, 20 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Company's Clinic ...

HOUSTON, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kirby Corporation ("Kirby") (NYSE: KEX) today announced the appointment of Tracy A. Embree as a new independent member of the Kirby Board of Directors effective February 16, 2026. She will stand for election at the annual meeting of the corporation in April of this year. Ms. Embree is the retired President of Otis Americas, a division of Otis Worldwide Corporation, and brings more than 25 years of global leadership experience across industrial operations, manufactu ...

Off The Hook YS Inc. Miami Supercenter Strategic move into physical global mega-destination site complements Off The Hook’s industry-leading AI-powered online marketplace, the largest of its kind for pre-owned boats in the U.S. Centralized hub to support the Company’s rapidly expanding inventory pipeline and international buyer network Wilmington, NC, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Off The Hook YS Inc. (NYSE American: OTH) (“Off The Hook Yachts” or “Off The Hook” or “the Company”), a vertically integ ...

VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Rio2 Limited (“Rio2” or the “Company”) (TSX: RIO; OTCQX: RIOFF; BVL: RIO) is pleased to announce that its executive team lead by Alex Black, Executive Chairman of the Board, and Andrew Cox, President & CEO, will attend BMO’s 35th Global Metals, Mining, and Critical Minerals Conference next week in Hollywood, Florida, to discuss its future growth plans for the Fenix Gold Mine and the newly acquired Condestable Mine. Rio2 is set to present on Wedn ...